Vistagen releases corporate presentation highlighting nose-to-brain neuroscience platform

Vistagen Therapeutics, Inc.

Presentation dated January 2026 describes nose-to-brain neurocircuitry for CNS disorders.
No financial data, pipeline updates, or milestones disclosed in the filing excerpt.
VTGN common stock trades on Nasdaq Capital Market.

item 7.01 item 9.01

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-001690

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.